Picard Medical, Inc. (PMI) Shareholder/Analyst Call Prepared Remarks Transcript
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Curtis Ellergodt Rothschild Investment LLC | 0.78 | $20.15 | $6.31 | -$13.84 | -68.68% |
Bobby Adusumilli SJS Investment Consulting Inc. | 18.34 | $161.24 | $120.49 | -$40.75 | -25.27% |
W. Travis McKinney HB Wealth Management LLC | 362.26 | $3,133.55 | $2,568.42 | -$565.13 | -18.03% |
Drew Phillips Fortitude Family Office LLC | 138 | $993.76 | $910.8 | -$82.96 | -8.35% |
Kevin Kroskey True Wealth Design LLC | 23 | $97 | $187.79 | $90.79 | 93.6% |
| Health Care Equipment & Supplies Industry | Healthcare Sector | Richard Fang CEO | AMEX Exchange | 71953R108 CUSIP |
| US Country | 75 Employees | - Last Dividend | 3 Aug 2026 Last Split | - IPO Date |
Picard Medical, Inc. is a forward-thinking medical device company that focuses on the design, manufacture, and marketing of innovative healthcare solutions. Established in 2021, the company operates from its headquarters in Tucson, Arizona, and has a global footprint, serving markets in the USA and Europe, as well as other international regions. The company stands as a subsidiary of Hunniwell Picard I, LLC, leveraging its resources and expertise to advance the development of life-saving medical technologies, particularly in the field of artificial hearts.
The SynCardia Total Artificial Heart (TAH) is a groundbreaking medical device designed for patients diagnosed with advanced heart failure. It serves as a bridge to heart transplantation or, in certain cases, as a long-term solution to replace the failing human heart. This innovative product mimics the essential functions of a normal heart, allowing patients to regain their quality of life while awaiting a suitable donor organ. The TAH is recognized for its exceptional performance and is a testament to Picard Medical's commitment to improving patient outcomes in the field of cardiology.